Comparative Pharmacology
Head-to-head clinical analysis: FEXINIDAZOLE versus LAMPIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXINIDAZOLE versus LAMPIT.
FEXINIDAZOLE vs LAMPIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexinidazole is a nitroimidazole derivative that enters the parasite and inhibits DNA synthesis by forming reactive metabolites, leading to cell death. It is active against Trypanosoma brucei gambiense.
Inhibits the enzyme G6PD (glucose-6-phosphate dehydrogenase) in Trypanosoma cruzi, leading to oxidative stress and parasite death.
500 mg orally twice daily for 10 days for trichomoniasis; 2 g orally single dose for giardiasis.
Nifurtimox (Lampit) for Chagas disease: adult dose 8-10 mg/kg/day orally in 3 divided doses for 90 days. For Chagas disease in children: 15-20 mg/kg/day orally in 3 divided doses for 90 days.
None Documented
None Documented
Approximately 8-12 hours in adults; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 20 hours. In hepatic impairment, half-life may be prolonged by up to 2-fold.
Primarily renal (60-70% unchanged), with 20-30% biliary/fecal.
Renal excretion of unchanged drug accounts for 10% of the dose; biliary/fecal excretion accounts for approximately 90%, mainly as metabolites.
Category C
Category C
Antiprotozoal
Antiprotozoal